Prescription drug · BLA
Briumvi (ublituximab) NDC 73150-150
Ublituximab 150 mg/6mL · Injection, Solution, Concentrate · Intravenous · TG Therapeutics, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 73150-150-06 | 73150015006 | 1 VIAL, SINGLE-DOSE in 1 CARTON (73150-150-06) / 6 mL in 1 VIAL, SINGLE-DOSEMarketed from Dec 28, 2022 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Briumvi
- Generic name (nonproprietary)
- ublituximab
- Active ingredients
- Ublituximab — 150 mg/6mL
- Dosage form
- Injection, Solution, Concentrate
- Route
- Intravenous
- Labeler
- TG Therapeutics, Inc.
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761238
- Marketing start
- Listing expires
- Other FDA classes
- CD20-directed Antibody Interactions (Mechanism)
- Identifiers
- Product ID 73150-150_4b34fc66-ea84-161b-e063-6294a90ac575SPL ID 4b34fc66-ea84-161b-e063-6294a90ac575SPL set ID 3a77cd8c-811b-407c-9140-d0c5c26435c2RxCUI 2626353, 2626359UNII U59UGK3IPCUPC 0373150150063
- Pharmacologic class
- CD20-directed Cytolytic Antibody
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N473150015006followed by a unit qualifier and the quantityPackage 73150-0150-06. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. BRIUMVI is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 , 14 ).
Excerpt only. Read the full label for complete information.